Holly Huang, PhD, MPH

Holly Huang, PhD, MPH has extensive experience in the biometrics field, having held various roles since 1998. Holly began their career as a Biostatistician at Merck in 1998, followed by a Senior Biostatistician role at Pfizer in 1999. From 2003 to 2015, they held the roles of Associate Director of Biostatistics and Senior Biostatistician at Sunovion Pharmaceuticals Inc. Holly then moved to Intarcia Therapeutics, Inc. in 2015, where they served as Head/Senior Director/Director of Biostatistics and SAS Programming. In 2018, they joined Albireo Pharma, Inc. as Senior Director/Head of Biostatistics and Programming. Most recently, they have been Vice President and Head of Biometrics at Angion since 2020, where they are responsible for providing strategic input and developing the Biometrics team. In 2022, they will take on a similar role at Denovo Biopharma, where they will be responsible for developing and implementing the strategic vision for Biometrics.

Holly Huang, PhD, MPH has an extensive education history. Holly obtained a Bachelor's degree from Nanjing University. Holly then went on to complete a Master of Science (MSc) in Statistics from Temple University in 1998. In 2005, they earned a Master of Public Health (MPH) from Walden University in the field of Public Health. Holly then completed their Doctor of Philosophy (PhD) in Epidemiology from Walden University in 2011, with an Area of Research in Applied Biostatistics in Chronic Disease Epidemiology. In 2013-2014, they obtained a Certificate Program in Health Economics and Outcomes Research from University of Washington through the Pharmaceutical Outcomes Research & Policy Program (PORPP). Additionally, they obtained a Health Economics and Outcome Research certification from University of Washington in June 2014.